Assessment of Anti-fungal Drugs Utilization Pattern Among Patients Attending at Zewditu Memorial Hospital, Addis Ababa, Ethiopia, 2022
DOI:
https://doi.org/10.14738/bjhr.1202.18505Keywords:
Anti-fungal, Utilization Pattern, Fungal infectionAbstract
Background: the inappropriate use of anti-fungal agents can cause adverse events, toxicity, unnecessary exposure and cost, and increased microbial resistance, which has important implications for morbidity and mortality. With a lack of adequate Information on how drugs are being prescribed and utilized, it is almost impossible to initiate a discussion on rational drug use or improvement on prescription habits and developing practical guidelines. Drug utilization might not necessarily provide answers on its own, but it contributes to rational drug use. Objective: To Assess anti-fungal agent utilization patterns among patients attending Zewditu Memorial Hospital, Addis Ababa, Ethiopia, 2022. Methodology: A Retrospective Cross-sectional study design was used. Data regarding patient characteristics, medications, diagnosis, dose and type of anti-fungal agent used were collected using data abstraction forms by reviewing the patient's medical card and medication charts. The data was entered into the SPSS 21 version for analysis. The analyzed data was interpreted and presented in charts, graphs and tables. Results: 124 anti-fungal agents were prescribed to 75 patients. Female patients received (n=66, 53.23%) of these prescriptions, and Male patients received (n=58, 46.77%).patients who were under 18 years old received (n=100, 80.6%), and patients who were 18 years old and above received (n=24, 19.3%).In this study, prescription of Fluconazole was(n=54, 44.4%) and Ketoconazole (n=55, 43.5%) while Clotrimazole was(n=9, 7.3%) and Terbinafine(n=6, 4.8%).the fungal infection of this patients were tinea capitis (n=48, 64%,) tinea unguium (n=13, 17.3%),tinea corporis(n=6, 8%)tinea pedis(n=7, 9.3%) tinea barbea (n=1, 1.3%). Conclusion: This study finding shows that Fluconazole was the most common anti-fungal drug prescribed orally, similar to elsewhere. However, oral Fluconazole was closely followed by Ketoconazole, which was the most frequently prescribed drug topically. This differed from other studies, meaning Clotrimazole was the most prescribed drug topically anti-fungal in different countries. Lastly, most studies support that Combination therapy of antifungals was more likely than Monotherapy.
References
Centers for Medicare & Medicaid Services. Drug Utilization Review (DUR), Medicaid; November 8, 2021.
Thomas J. Walsh and Dennis M. Dixon. Spectrum of Mycoses Chapter 75. Medical Microbiology. 1996.
S. C. PRADHAN, D. G. SHEWADE, C. H. SHASHINDRAN, 1. S. BAPNA. Drug
utilization studies. THE NATIONAL MEDICAL JOURNAL OF INDIA. 1988; 1(4185): p. 185.
Sema FD, Asres ED, Wubeshet BD, Evaluation of Rational Use of Medicine. Evaluation of Rational Use of Medicine. 2021; 2021:10: p. 51—63.
World Health Organization. Introduction to Drug Utilization Oslo, Norway; 2003.
Wiley B. Drug Utilization Research: Methods and Applications Monique Elseviers BWABAMARBMBIEBGJKEPKTVVPRVS, editor.: John Wiley & Sons; 2016.
Krzyzaniak N, Pawlowska I, Bajorek B. Review of drug utilization patterns in NICUs worldwide. J Clin Pharm Ther. 2016; 41: pp. 612–620.
Arnold TM DESGea. Traditional and emerging anti-fungal therapies. Proc Am Thorac Soc. 2010; 7(3): p. 222–228.
BP. Superficial fungal infections. Pediatr Rev. 2012; 33(4): p. e22-e37.
Vos T. FAD, NM, LR,MC,EM,SK,SJA,AS,AV,ea. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): p. 2163–2196.
D.W. D. The ambitious '95–95 by 2025' roadmap for diagnosing and managing fungal diseases. Thorax. 2015; 70(7).
Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017; 3(4): p. 57.
Tokarska K MICMWA. Immunometabolic disorders in the pathogenesis of systemic lupus erythematosus. Postepy Dermatol Alergol. 2019; 36(5): p. 513-518.
Denning DW. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos Trans R Soc Lond B Biol Sci. 2016; 371(1709).
Rita O. Oladele, Iorhen E. Akase, Ahmed H. Fahal, Nelesh P. Govender, Martin Hoenigl, Jean Pierre Gangneux, Tom M. Chiller, David W. Denning, Oliver A. Cornely, Arunaloke Chakrabarti. Bridging the knowledge gap on mycoses. The Lancet Microbe. 2022; 63(3): p. 244-249.
Amoaning Harry. Determinants of Anti-fungal use in the GA-South Municipality; Implications for antimicrobial stewardship. 2018.
A. Colombo, M. Nucci, Benjamin J Park, S. Nouer, B. Arthington-Skaggs, D. D. da Matta, D. Warnock, J. Morgan. Epidemiology of Candidemia. Biology Journal of Clinical Microbiology. 2006.
Cole DC, Govender NP, Chakrabarti A, Sacarlal J, Denning DW...; doi: 17(12). Improvement of fungal disease identification and management: combined health systems and public health approaches. Lancet Infect Dis. 2017; 17(12): p. 412-419.
De Souza MC, Dos Santos AG, Reis AM. Drug utilization study of systemic anti-fungal agents in a Brazilian tertiary care hospital. Int J Clin Pharm. 2016; 38(6): p. 1398-1406. 240
Sandeep Sundriyal, Rohit K. Sharma and Rahul Jain. Current Advances in Anti-fungal Targets and Drug Development: Bentham Science; 2006.
WHO Drug Information. WHO Drug Information. Rio de Janeiro, Brazi.
Mahmoud A. Ghannoum, Louis B. Rice. Anti-fungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. 1999; 12(4): p. 501–517.
Tafese B. Tufa and David W. Denning. The Burden of Fungal Infections in Ethiopia. J. Fungi 2019. 2019; 5(4).
Al Balushi KA, Alzaabi MA, Alghafri F. Prescribing Pattern of Anti-fungal Medications at a Tertiary Care Hospital in Oman. J Clin Diagn Res. 2016; 10(12).
Wang Y, Van Driel ML, McGuire TM, Hollingworth SA. Trends in systemic anti-fungal use in Australia, 2005-2016: a time-series analysis. Jpn J Infect Dis. 2021.
Liliana Scorzoni, Ana C. A. de Paula e Silva, Caroline M. Marcos, Patrícia A. Assato, Wanessa C. M. A. de Melo, Haroldo C. de Oliveira, Caroline B. Costa-Orlandi, Maria
J. S. Mendes-Giannini and Ana M. Fusco-Almeida, Anti-fungal Therapy: New Advances in the Understanding and Treatment of Mycosis. 2017;(36).
Naaz R CSNUPVBCRKCBSS. Prospective Observational Study on Prescribing Pattern of Anti-fungal Drugs in the 400 Outpatient Department of Dermatology in a Tertiary Care Hospital. Biomed Pharmacol J. 2021; 14(1).
Mohammad Daud Ali, Munfis Patel, Nuzhat Banu, Ayaz Ahmad, Yousif Amin Hassan. A retrospective study on drug utilization pattern and cost-utility analysis of anti-fungal drugs. Journal of Pharmaceutical Health Services Research. ; 12(1).
Sourabh B. Desai, Rushikesh N. Chougale, Akash D. Patil. Drug utilization Pattern and Analysis of anti-fungal drugs used by Dermatology. 2021.
Manohar M SA. An observational and cross-sectional study of prescribing pattern of anti-fungal drugs in a tertiary care center of Bihar. IP Int J Comprehensive Adv Pharmacol. 2021; 6(4): p. 177-180.
Abebaw Tegegne and Fentaw Bialfew. Prescribing pattern for skin diseases in dermatology OPD at Borumeda Hospital, Northeast Ethiopia. Pain studies treatment. 2018; 6(1).
Mushi, M. F., Masewa, B., Jande, M., Mirambo, M. M., & Mshana, S. E. Prevalence and factor associated with over-the-counter use of anti-fungal agents', in Mwanza city, Tanzania. Tanzania Journal of Health Research. 2017; 19(1).
Xing Chen, Biao Ren, Ming Chen, Ming-Xi Liu, Wei Ren, Quan-Xin Wang, Li-Xin Zhang, Gui-Ying Yan. ASDCD: anti-fungal synergistic drug combination database. PLoS ONE. 9(1).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Samrawit Teame Gebremariam, Robel Nasser Abafita, Dagmawi Mulugeta Fentaw, Eden Kebede Telila, Hosaena Alemayehu Jeldu, Betelhem Alemu Mulugeta, Biruk Getachew Woldie, Meron Tafa Baissa, Mekdes Molla Wollel, Bethel Tadesse Mandefro, Abrham Workineh Azale, Tewodros Challa Tollosa

This work is licensed under a Creative Commons Attribution 4.0 International License.